Long-term Lamivudine: experience in hepatitis B patients in a tertiary centre in

StephenW

Long-term Lamivudine: experience in hepatitis B
patients in a tertiary centre in Western Australia
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J FLEXMAN,2 W CHENG1
1Department of Gastroenterology and Hepatology,
2Infectious Diseases, Royal Perth Hospital, WA
Long-term treatment with Lamivudine is associated with high rates of
resistance, but some patients showed long term good viral suppression.
The objective of the study is to describe the clinical, biochemical and
virological outcomes of the patients who are treated with Lamivudine for
chornic hepatitis B (CHB) in Royal Perth Hospital, WA over the period of
15 years from 1995 to 2010.
Methods
Retrospective descriptive study of all patients with CHB seen
at the Liver Service. The primary end-point was HBeAg seroconversion,
and loss of HBV DNA. The secondary end-points included the proportion
of the patients who are still on Lamivudine, serologic recurrence and reappearance
of HBV DNA. Data are collected from the Pharmacy records,
patients’ case notes and computerised laboratory investigations from iSoft
patient management database.
Results
A total of 145 patients who were treated with Lamivudine over
the last 10 years. By the end of 2010, there were 37 patients (25.52%) on
Lamivudine therapy. There was no difference in age or gender distribution
between those who were still on Lamivudine and those who were not. Of
the 145 patients, 18 (12.41%) achieved HBeAg seroconversion. Out of the
patients who achieved HBeAg seroconversion only 2 remained on
Lamivudine at the end of the study period. Out of the total of 145 patients,
12 achieved HBsAg loss and 4 patients lost HBsAg while on Lamivudine
therapy. Of the total 37 patients currently on Lamivudine, 18 (48.64%)
have negative HBV DNA. By the end of 2010, a total of 33 patients
remained negative for HBV DNA. However of the 33 patients who have
negative HBV DNA and still on the drug, only 1 patient achieved HBeAg
seroconversion and 2 patients lost HBeAg, but remained anti HBe negative;
no patients lost HBsAg. At the end of the study period 21 out of the
37 were on Lamivudine monotherapy.
Summary
Our data are consistent with previous published data. There
was no correlation of HBeAg seroconversion to Age, Sex, or pre-treatment ALT.

StephenW

谷歌翻译不是100％准确，仅供参考使用。

高利率与长期与拉米夫定治疗
阻力，但有些患者表现为长期良好的抑制病毒。
这项研究的目的是描述的临床，生化和
拉米夫定治疗的患者的病毒学结果
慢性乙型肝炎（CHB）在皇家珀斯医院，WA在期
15年从1995年至2010年。
方法
慢性乙型肝炎患者的回顾性描述性研究
在肝服务。主要终点是HBeAg血清学转换，
和HBV - DNA的损失。二级终点包括的比例
患者仍然拉米夫定，血清学复发和再现
HBV - DNA。从药房记录数据的收集，
患者的案例说明，从普华电脑实验室调查
病人管理数据库。
结果
一个与拉米夫定治疗的145例患者的总
过去的10年。到2010年底，有37例（25.52％）
拉米夫定治疗。有没有年龄或性别的分布的差异
那些仍然对拉米夫定和那些没有之间。在
145例患者中，18（12.41％）实现HBeAg血清学转换。出了
实现HBeAg血清转换的患者中，只有2仍
拉米夫定在研究结束。共有145例患者中，
12取得HBsAg消失，4例患者失去了乙肝表面抗原，同时对拉米夫定
治疗。目前拉米夫定，18总额的37例（48.64％）
有负面的HBV - DNA。到2010年底，共33例
HBV - DNA仍为阴性。然而，人的33例患者
阴性HBV DNA和上药，只有1例患者实现HBeAg的
失去了HBeAg的血清转换和2例，但仍然抗HBe阴性;
没有患者失去了乙肝表面抗原。在研究期间21月底
37名对拉米夫定单一治疗。
摘要
我们的数据与以前公布的数据是一致的。有
没有年龄，性别，或治疗前的ALT的HBeAg血清转换的相关性。

买平安的

如果是原创   中国论坛最好用正规中文
如果转文章   请注明出处和链接，不要随便抄袭或者引用不确定的消息

StephenW

买平安的 发表于 2011-8-6 19:18
如果是原创   中国论坛最好用正规中文
如果转文章   请注明出处和链接，不要随便抄袭或者引用不确定的消息 ...

这些论文作者和他们的工作地址。他们是来自澳大利亚。
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J FLEXMAN,2 W CHENG1
1Department of Gastroenterology and Hepatology,
2Infectious Diseases, Royal Perth Hospital, WA

买平安的

StephenW 发表于 2011-8-6 20:31
这些论文作者和他们的工作地址。他们是来自澳大利亚。
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J F ...

转帖论文，更加应注明出处。
应该尊重论文作者和出版物的版权